Jazz Pharmaceuticals Plc (JAZZ) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Incyte Corp.

Alnylam Pharmaceuticals, Inc.

Repligen Corp.

Neurocrine Biosciences, Inc.

United Therapeutics Corp.

Jazz Pharmaceuticals Plc

Royalty Pharma Plc

Sarepta Therapeutics, Inc.

Roivant Sciences Ltd.

Walgreens Boots Alliance, Inc.

Viatris, Inc.

Why is Jazz Pharmaceuticals Plc ?

Poor Management Efficiency with a low ROCE of 9.96%

The company has been able to generate a Return on Capital Employed (avg) of 9.96% signifying low profitability per unit of total capital (equity and debt)

Healthy long term growth as Net Sales has grown by an annual rate of 13.02%

The company declared negative results in Mar'25 after positive results in Dec'24

NET PROFIT(HY) At USD 73.35 MM has Grown at -56.56%
ROCE(HY) Lowest at -10.84%
EPS(Q) Lowest at USD -11.74

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 44.80%, its profits have risen by 16.5% ; the PEG ratio of the company is 0.7

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating Performance

The stock has generated a return of 44.80% in the last 1 year, much higher than market (S&P 500) returns of 12.33%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Jazz Pharmaceuticals Plc should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jazz Pharmaceuticals Plc for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

Jazz Pharmaceuticals Plc

37.22%

1.66

39.17%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

13.02%

EBIT Growth (5y)

0.60%

EBIT to Interest (avg)

2.75

Debt to EBITDA (avg)

2.97

Net Debt to Equity (avg)

0.67

Sales to Capital Employed (avg)

0.41

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

9.96%

ROE (avg)

10.20%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.64

EV to EBIT

16.25

EV to EBITDA

7.69

EV to Capital Employed

1.38

EV to Sales

2.38

PEG Ratio

0.68

Dividend Yield

ROCE (Latest)

8.51%

ROE (Latest)

11.59%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

INVENTORY TURNOVER RATIO(HY)

Highest at 2.09 times

INTEREST COVERAGE RATIO(Q)

Highest at 594.91

RAW MATERIAL COST(Y)

Fallen by 0.98% (YoY

CASH AND EQV(HY)

Highest at USD 4,241.83 MM

-7What is not working for the Company

NET PROFIT(HY)

At USD 73.35 MM has Grown at -56.56%

ROCE(HY)

Lowest at -10.84%

EPS(Q)

Lowest at USD -11.74

Here's what is working for Jazz Pharmaceuticals Plc

Interest Coverage Ratio

Highest at 594.91

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Inventory Turnover Ratio

Highest at 2.09 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Cash and Eqv

Highest at USD 4,241.83 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by 0.98% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 174.01 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Jazz Pharmaceuticals Plc

Net Profit

At USD 73.35 MM has Grown at -56.56%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

EPS

Lowest at USD -11.74

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)